RecruitingNCT07281391

IOP Reduction in Pigmentary Glaucoma Using DSLT

Direct Selective Laser Trabeculoplasty Providing Effective Intraocular Pressure Reduction in Pigmentary Glaucoma Patients


Sponsor

Mann Eye Institute

Enrollment

45 participants

Start Date

Mar 19, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This study is a single-site, single-arm, prospective, observational study of IOP reduction after DSLT. Subjects will be assessed up to 12 months post-operatively. Clinical evaluations will include IOP and number of glaucoma medications.


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Voyager DSLT for people with pigmentary dispersion glaucoma and pigmentary dispersion syndrome. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEVoyager DSLT

DSLT is an innovative adaptation of traditional SLT. Rather than using a gonioscopic lens, DSLT applies laser energy directly through the limbus to the trabecular meshwork in a few seconds.


Locations(1)

Mann Eye Institute

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07281391


Related Trials